Policy & Regulation
AstraZeneca reports survival gains in Phase III bladder cancer trial
14 May 2026 - Biopharmaceutical company AstraZeneca plc (STO:AZN) (LON:AZN) (NYSE:AZN) reported on Thursday that interim Phase III VOLGA trial results showed that perioperative Imfinzi combined with n...
Ipsen presents Phase II corabotase data at SCALE 2026 symposium
14 May 2026 - French biopharmaceutical company Ipsen (Euronext Paris:IPN) (ADR:IPSEY) announced on Thursday that Phase II data from its LANTIC trial evaluating corabotase for glabellar lines will be p...
SOPHiA GENETICS and Synnovis partner to expand NHS liquid biopsy testing
...
Voyager Technologies secures ISS mission management contract with Exobiosphere
13 May 2026 - Defence and space technology company Voyager Technologies (NYSE: VOYG) and space biotechnology company Exobiosphere announced on Wednesday that the companies have signed a mission manage...
Kelun-Biotech's SKB118 PD-1 x VEGF bispecific antibody receives Chinese regulatory Investigational New Drug approval
13 May 2026 - Sichuan Kelun-Biotech Biopharmaceutical Co, Ltd (6990.HK) a China-based biopharmaceutical company, announced on Tuesday that it has received a clinical trial notice from China s Center f...
WuXi Biologics named in 2026 Dow Jones Best-in-Class World Index and Emerging Markets Index
13 May 2026 - WuXi Biologics (2269.HK), a China-based global Contract Research, Development and Manufacturing Organisation (CRDMO), announced on Tuesday that, in recognition of its continued efforts a...